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Abstract
Mannose-binding lectin (MBL) comprises an oligomeric serum protein that is a member of the collectin class of the C-type lectin super-
family. Its deﬁciency is genetically determined and confers predisposition to recurrent infections as well as increased infection severity.
This correlation has been demonstrated in recurrent furunculosis caused by Staphylococcus aureus, and in pneumococcal and Candida
infections. The present study aimed to determine whether there is a correlation between MBL serum levels and recurrent urinary tact
infections (UTI) in pre-menopausal women. The present aged-matched double-blind controlled study was conducted in 100 pre-meno-
pausal adult women: 50 who suffered from recurrent UTI and 50 without UTI. The MBL concentration was measured in a single serum
sample from each patient using an enzyme-linked immunosorbent assay. MBL serum levels [median (range)] were 2500 (4–12 000) ng/mL
and 2105 (4–22 800) ng/mL for the research and control groups, respectively. The results from the two groups were compared and
were not statistically different (p 0.4). According to these results, MBL serum levels are not associated with an increased risk for
recurrent UTI in pre-menopausal women.
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Introduction
Mannose-binding lectin (MBL), also named mannose or man-
nan-binding protein, comprising an oligomeric serum protein,
is a member of the collectin class in the C-type lectin super-
family that plays a central role in the acute phase of infections.
MBL has the capacity to recognize carbohydrate patterns
found on the surface of a large number of pathogenic micro-
organisms, including bacteria, viruses, protozoa and fungi.
Binding of MBL to a micro-organism results in activation of the
classical complement pathway, long before speciﬁc antibodies
are formed, eventually leading to the death of the pathogen
[1–4]. Reduced plasma levels of MBL may impair the normal
innate immune response and increase susceptibility to infec-
tions [5]. MBL deﬁciency occurs in 20–25% of the population,
which is a relatively high incidence compared to other deﬁ-
ciencies of the complement system [6,7].
Variability in plasma MBL levels and function among the
population correlates with multiple polymorphisms of the
MBL2 genes. Low plasma MBL levels and impaired function
are seen in structural gene homozygosity and the LX pro-
moter haplotype.
A relationship between low MBL serum levels and recur-
rent furunculosis caused by Staphylococcus aureus [8] and
severe pneumococcal infections [9,10] has been reported.
On the basis of a laboratory model, Ip and Lau [11] con-
cluded that MBL has also a signiﬁcant inﬂuence on the host
innate immunity against Candida albicans.
Urinary tract infection (UTI) is one of the most frequent
bacterial infections worldwide [12]. Pathogenesis and risk
factors for recurrent UTI in pre- and post-menopausal
women have been extensively described [13–16]. The major
pathogen causing more than 90% of UTI in young women is
Escherichia coli and Shang et al. [17] demonstrated that this
bacterium demonstrates a high binding capacity to MBL.
In addition, puriﬁed recombinant human MBL was found
to enhance phagocytosis of E. coli directly by acting as a
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bridge between macrophages and the target E. coli [18].
Another study found that patients with MBL-2 genotypes
associated with serum MBL deﬁciency undergoing acute
pyelonephritis caused by E. coli have a higher risk of develop-
ing septic shock [19].
However, Li et al. [20] have postulated a molecular theory
of complement activation during colonization of urinary epi-
thelium by E. coli that could support a lack of association
between low serum levels of MBL and UTI. To the best of
our knowledge, these issues have not been investigated pre-
viously in a clinical setting.
In the present age-matched case–control study, we aimed
to determine whether there is any association between MBL
serum levels and recurrent UTI in pre-menopausal women.
Materials and Methods
Pre-menopausal adult (age >18 years) women suffering from
recurrent UTI were enrolled in this case–control study.
Recurrent UTI was deﬁned as two documented episodes of
UTI in the past 6 months, or a history of three or more epi-
sodes in 1 year. A control group was also enrolled, including
an age-matched (±3 year) woman without recurrent UTI for
every woman in the research group. Controls were ran-
domly selected among nursing students, hospital personnel
and patients at two outpatient clinics.
From every woman in the study, a single peripheral blood
sample was taken at enrollment and serum was separated
within a maximum of 4 h and frozen at )70C. An additional
citrated blood sample was taken and kept frozen for further
possible genetic investigation. After providing their written
informed consent, the women ﬁlled in a questionnaire including
demographic data and clinical information that were relevant
to UTI, such as the number of documented UTI episodes and
prophylactic antimicrobial or replacement hormone therapy.
All serum samples were thawed at the same time and
quantitatively tested for MBL level using MBL Oligomer
ELISA kit (BioPORTO Diagnostics, Gentofte, Denmark).
This CE marked kit allows the testing of MBL in range
2–3000 ng/mL. Test results were read in a manual ELISA
reader and plotted. All internal controls ﬁtted the expected
results according to the manufacturer’s instructions. Sera
showing levels higher than 3000 ng/mL were diluted 1:100
and retested to reach endpoint.
Statistical analysis was performed using chi-squared for
dicotomic parameters and Student’s t-test for serial numbers.
This study was approved by the local ethics committee.
Results
In total 100 women (50 in the research group and 50 in the
control group) were included. Age-matching between groups
was successfully performed with a median (range) of 32 (18–
51) years for the research group and 34 (20–53) years for
the control group (p 0.44).
The mean (range) number of documented episodes of UTI
in the past year in the research group was 3 (0–6) and none
for the control group. Among the 50 patients in the research
group, seven had not suffered any episode of UTI in the pre-
vious year and two had experienced only one episode. How-
ever, these nine patients were enrolled in the research
group as having a documented history of recurrent UTI in
the past. Of these nine patients, four were receiving prophy-
lactic nitrofurantoin macrocrystals and ﬁve had been con-
suming cranberry juice on a daily basis during the last year.
The demographic characteristics of the two groups are
compared in Table 1. Mean (range) and median levels of
MBL were 2820 (4–12 000) ng/mL and 2500 ng/mL in the
research group vs. 3466 (4–22 800) ng/mL and 2105 ng/mL
in the control group (p not signiﬁcant). The distribution of
TABLE 1. Clinical and demographic characteristics of
patients in research and control groups
Research
group,
n (%)
Control
group,
n (%) p
Recurrent UTI within family 21 (42.0) 4 (8.0) 0.0001
Recurrent non-UTI infections 5 (10.0) 2 (4.0) 0.23
UTI in childhood 11 (22.0) 1 (2.0) 0.002
UTI in pregnancy 10 (20.0) 5 (10.0) 0.16
Sex activity related UTI 22 (44.0) 0 0.0000
Upper UTI in the past 23 (46.0) 2 (4.0) 0.0001
Hospitalization due to UTI 13 (26.0) 1 (2.0) 0.0001
Previous ABTx for UTI 18 (36.0) 0 0.0000
Prophylactic ABTx for UTI 18 (36.0) 0 0.0000
Birth control use 19 (38.0) 3 (6.0) 0.0001
Cranberry juice prophylactic use 27 (54.0) 0 0.0000
ABTx, antibiotic treatment; UTI, urinary tact infection.
TABLE 2. Mannose-binding lectin (MBL) serum levels by
category in both groups
MBL (ng/mL)
Research group
n (%)
Control group
n (%) p
0–10 2 (4.0) 5 (10.0) 0.23
11–100 3 (6.0) 4 (8.0) 0.70
101–1000 11 (22.0) 8 (16.0) 0.44
1001–2000 7 (14.0) 7 (14.0) 1.0
2001–3000 3 (6.0) 6 (12.0) 0.29
>3000 24 (48.0) 20 (40.0) 0.42
Total 50 (100) 50 (100)
Mean value 2500 2105 0.40
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MBL serum levels in the two groups is presented in six
incremental categories in Table 2 and graphically presented
in Fig. 1 indicating that no cut-off value could be established
between the groups.
Discussion
The role of MBL in the innate immune system has been
extensively described. Once MBL recognizes a microbial sur-
face, the complement pathway is activated, enhancing opso-
nophagocytosis [21]. A lack of MBL may predispose the host
to recurrent infections, Super et al. [1] described a correla-
tion between an MBL-dependent opsonic defect in human
serum and a phenotype of recurrent infection. Analysis of
the MBL gene has revealed at least seven distinct MBL haplo-
types in humans, four of which express low MBL serum
levels [22]. There is a high rate of haplotype variation in dif-
ferent human populations, with heterozygosity rates ranging
from 15% in Caucasians to 30% in African populations [6,7].
Low serum levels of MBL have been associated with
increased risk of recurrent furunculosis [8], severe infections
caused by Streptococcus pneumoniae [9,10], and tuberculosis
[23], and a possible, although not deﬁnitely proven, associa-
tion with cryptosporidiosis [24]. In addition, the role of MBL
in the innate defence against C. albicans has been postulated
by Ip and Lau [11] and a higher frequency of the MBL2
codon 54 morphotype has been found in Belgian women
with recurrent vulvovaginal candidosis [25]. Moreover, MBL
deﬁciency may play an important role in speciﬁc populations
at risk; for example, a signiﬁcant association between low
concentrations of MBL and serious infections in patients
receiving chemotherapy has been reported [26].
On the other hand, other studies have found a lack of
association between low serum levels of MBL and Helicobact-
er pylori seropositivity, HPV infection and infections in
patients with systemic lupus erythematosus [27–29].
Equally, in a population-based study performed in 9245
individuals, no evidence for differences in infectious disease
or mortality between MBL-deﬁcient subjects and controls
was found [30].
UTI is one of the most common bacterial infections in
humans. Women are more likely than men to develop recur-
rences, and do so especially in the post-menopausal era. How-
ever, recurrent UTI in pre-menopausal women is not an
infrequent phenomenon: many young fertile women suffer
from this very unpleasant and sometimes dangerous infection.
Given the fact that both UTI and MBL-defective halotypes
are widely spread in the human population, we decided to
investigate the relationship between serum MBL levels and
recurrent UTI, as a ﬁrst step for a further genetic investiga-
tion to determine whether any association exists.
We decided to focus ﬁrst on pre-menopausal women,
representing a more homogeneous group of patients, in that
post-menopausal women often present co-morbidities such
as diabetes or urogynaecological problems and have lower
oestrogen secretion. All these factors were identiﬁed as
potential confounders. For these reasons, post-menopausal
women were not included in the present study.
With this goal in mind, we performed an age-matched
case–control study in a total of 100 women volunteers, with
half of them suffering from recurrent UTI.
The categorical (Table 2) and graphical (Fig. 1) distribution
of MBL serum levels in the two groups revealed no signiﬁ-
cant differences between the groups. Moreover, the median
value among patients in the control group was slightly lower
(but not statistically signiﬁcantly) compared to those in the
research group.
The lack of association between low MBL levels and
recurrent UTI found by us in the present study could be
explained by the fact that MBL does not appear to be the
principal pathway for complement activation during urinary
infections by E. coli. As postulated by Li et al. [20], the initia-
tion of complement activation during colonization of urine
epithelium by E. coli depends mainly on the classical or the
alternative pathway, as related to complement protein
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FIG. 1. Mannose-binding lectin serum levels of patients in research
and control groups.
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concentration. According to Li et al. [20], the MBL pathway
has little role in the opsonization of uropathogenic E. coli.
To the best of our knowledge, the present study is the
ﬁrst to provide clinical results supporting this molecular
hypothesis.
One of the limitations of the present study concerns the
potential use of the samples in a further genetic investigation:
the ethical stipulations prevented any identiﬁcation of individ-
ual samples that could allow matching of epidemiological data
to the MBL serum levels obtained. Thus, the results of the
present study could only be compared between groups and
no regression analysis could be performed to test whether a
low MBL serum level is an independent risk factor for recur-
rent UTI. However, given the results detailed in Table 2, this
possibility appears to be very unlikely.
Other limitations of the present study were the relatively
small number of cases that were enrolled and the fact that
participants were not asked about their sexual activity, which
is a well known risk factor for UTI in young women. How-
ever, the data obtained convinced us not to perform the
genetic investigation of our patients that was planned origi-
nally, given the fact that we did not ﬁnd phenotypic differ-
ences in MBL between the research and control groups.
The results obtained reveal no association between low
MBL serum levels and recurrent UTI in pre-menopausal
women, suggesting that MBL deﬁciency does not play a role
in recurrent UTI in pre-menopausal women. This lack of
association should be conﬁrmed in studies including a larger
number of cases.
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